7:30 am Check-In & Coffee
8:20 am Chair’s Opening Remarks
Unlocking Precision Medicine: Leveraging Bioinformatics and Multiomics for Targeted Solutions to Age-Related Diseases
8:30 am Overview of Clinical and Regulatory Framework For Age-Related Drug Development
Synopsis
- How FDA thinks, what they want, and how to work with them
- Understanding the science of drug development
- How to execute drug development
9:00 am Harnessing Transcriptomics for Precision Age-Related Therapeutics
Synopsis
- Analysing genomics data for oncology targets
- Developing computational approaches for large-scale genomics data
- Applying large scale genomic data to age-related disease targets
9:30 am Exploring Functional Genomics for Precision Age-Related Therapeutics
Synopsis
- Analysing gene expression pathways to understand how transcriptomic data can illuminate process implicated in aging
- Exploring the use of transcriptomics in biomarker identification to gain insights into the molecular signatures of age-related diseases
- Examining the temporal dynamics of gene expression changes during aging
10:00 am Leveraging AI to Identify Cellular Senescence Heterogeneity Across AgeRelated Diseases for therapeutic Interventions
Synopsis
- Senolytics are a powerful therapeutic opportunity to treat age-related chronic conditions
- An analogy with cancer cells: Cellular senescence is pleiotropic and characterised by a high degree of heterogeneity
- Not all states of cellular senescence are relevant therapeutic targets
- Introducing Alembic: AI computational single-cell multi-omics platform developed to elucidate the heterogeneity between cell types and cell states for novel first-in-class drug discovery
10:30 am Morning Break & Networking
11:00 am An Overview of the Epigenetic Mechanisms of Aging
Synopsis
- Understanding the fundamental concepts underlying aging at the epigenetic level
- Explore the potential of epigenetic interventions as novel strategies for extending health span and lifespan
- Explore the role of DNA methylation, histone modifications, and non-coding RNAs in regulating the aging process
Securing Funding and Partnerships in a New and Growing Field
11:30 am Panel Discussion – Securing Partnerships in the Age-Related Therapeutics Space
Synopsis
- Discussing strategies to get investors and big pharma comfortable with the concept of an emerging field
- Tackling the complexities of Intellectual Property ownership when forming partnerships and collaborations
- Why is now the right time to form a collaboration?
12:30 pm Lunch
Studying Biological Clocks for Therapeutic Breakthroughs
1:30 pm Adropin: a circadian neuropeptide and potentially modifiable risk indicator of aging-related cognitive decline
Synopsis
- Identified a small, secreted peptide highly expressed in the human nervous system. Expression profiling indicates a circadian pattern and positive relationships with gene networks involved in mitochondrial and synaptic functions
- Expression in the brain declines with aging; in humans low circulating levels predict increased risk of cognitive decline in community-dwelling adults aged >70 years
- Preclinical studies using mouse models indicate increasing levels can reverse aging-related cognitive decline
2:00 pm Panel discussion: A Deep-Dive Into Biological Clocks for Therapeutics Breakthroughs
Synopsis
- Leveraging biological clocks in the development of age-related therapeutics
- Using tissue-specific biological clocks to develop interventions that target systemic aging
- Deciphering whether alterations in biological clocks directly contribute to aging